21st Century Treatments for the Sustainable Elimination of Leishmaniasis (360G-Wellcome-212346_Z_18_Z)
The programme goal is to transform leishmaniasis treatment from the use of toxic, painful injectable antimonial therapies to a simple, orally acting and well tolerated treatment easy to use in resource poor settings. The strategy will rely on developing an oral combination of two co-administered drugs to maximise efficacy, reduce dose and duration of treatment, minimise side effects, and prevent or delay the emergence of drug resistance. DNDi, GlaxoSmithKline, the University of Dundee, Anacor, Pfizer, The Global Alliance for TB Drug Development, Takeda Pharmaceuticals and Celgene have built an unprecedented portfolio of candidates against Leishmania parasites. This pipeline is a strong basis for advancing towards oral leishmaniasis therapy(ies), to overcome attrition in development and identify one or more combination treatments for visceral leishmaniasis as the priority disease and also potentially for cutaneous leishmaniasis. This programme will evaluate 10 candidates aiming to select two orally-active New Chemical Entities (NCEs) ready for testing as a combination in Phase II studies in patients, maintaining a backup option of a combination of a single NCE with the existing oral drug, miltefosine. In the longer term, the programme aims to deliver new oral, high efficacy and affordable drug combinations for leishmaniasis.”
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
Amount Awarded | 10044444 |
Applicant Surname | Mowbray |
Approval Committee | Science, Innovation and Translation Programme Advisory Group |
Award Date | 2018-09-30T00:00:00+00:00 |
Financial Year | 2017/18 |
Grant Programme: Title | Innovations Priority Project |
Internal ID | 212346/Z/18/Z |
Lead Applicant | Dr Charles Mowbray |
Other Applicant(s) | Dr Fabiana Alves, Dr Jean-Yves Gillon, Dr Stephen Robinson |
Partnership Value | 10044444 |
Planned Dates: End Date | 2022-03-24T00:00:00+00:00 |
Planned Dates: Start Date | 2019-01-25T00:00:00+00:00 |
Recipient Org: Country | Switzerland |
Region | International |